Neumora Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
NMRA$0.50+3.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements (Unaudited)Condensed Consolidated Balance Sheets
Condensed Cons olidated Balance Sheets
(in thousands)
| March 31,2026 | December 31,2025 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $147,072 | $182,530 |
| Prepaid expenses and other current assets | 6,362 | 8,007 |
| Total current assets | 153,434 | 190,537 |
| Property and equipment, net | 32 | 40 |
| Operating lease right-of-use assets | 358 | 417 |
| Other assets | 53 | 53 |
| Total assets | $153,877 | $191,047 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $5,057 | $3,379 |
| Accrued liabilities | 24,767 | 28,788 |
| Operating lease liabilities, current portion | 291 | 284 |
| Total current liabilities | 30,115 | 32,451 |
| Long term debt, net | 52,963 | 54,532 |
| Operating lease liabilities, noncurrent | 119 | 193 |
| Total liabilities | 83,197 | 87,176 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Common stock | 18 | 17 |
| Additional paid-in capital | 1,308,269 | 1,288,003 |
| Accumulated deficit | (1,237,607) | (1,184,149) |
| Total stockholders’ equity | 70,680 | 103,871 |
| Total liabilities and stockholders’ equity | $153,877 | $191,047 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.